AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15088136
Drug: Home infusions
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home infusions
Trial: 11427834
Drug: Propofol PCS
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol PCS (0.3 mg/kg bolus, zero lockout)
Trial: 11427834
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.05 mg/kg bolus, 1 mg increments as required)
Trial: 3145014
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cephradine
Trial: 3145014
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g mezlocillin
Trial: 3145014
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g cephradine
Trial: 19362286
Drug: Stapled transanal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stapled transanal rectal resection alone or associated with transobturator tape, vaginal repair of the enterocele, or vaginal hysterectomy
Trial: 19362286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rectal and urogynecologic surgery with vaginal hysterectomy
Trial: 8701892
Drug: Bolus recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus recombinant urokinase (rUK) administered as three bolus infusions of 1 million U over a 24-hour period
Trial: 8370856
Drug: Nondirective (ND)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondirective (ND) therapy
Trial: 29432644
Drug: BF-200 ALA
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF-200 ALA (5-aminolaevulinic acid gel)
Trial: 29432644
Drug: MAL (methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL (methyl aminolaevulinate cream)
Trial: 19468050
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (general)
Trial: 12826700
Drug: recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle-stimulating hormone (recFSH) 2 x 225 IU per week + hCG
Trial: 12826700
Drug: recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle-stimulating hormone (recFSH) 3 x 150 IU per week + hCG
Trial: 12826700
Drug: hCG alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG alone (pre-treatment)
Trial: 12826700
Drug: Combined gonadotropin
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined gonadotropin treatment
Trial: 7793186
Drug: Plain 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain 0.15% bupivacaine (150 mg.100 ml‐1)
Trial: 7793186
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with adrenaline (1.5 micrograms ml‐1)
Trial: 1828183
Drug: LHRH analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH analogue Zoladex (administered subcutaneously every 28 days)
Trial: 6758745
Drug: Aspirin (1950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1950 mg/day orally)
Trial: 6758745
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg/day orally)
Trial: 16710890
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (Group B)
Trial: 9089426
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (7.8 mg/24 hr)
Trial: 9089426
Drug: Baseline (drug-free)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (drug-free) response to tyramine
Trial: 7824763
Drug: Adinazolam 30
RxNorm normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam 30 mg/day
Trial: 7824763
Drug: Adinazolam 60
RxNorm normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam 60 mg/day
Trial: 7824763
Drug: Adinazolam 90
RxNorm normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam 90 mg/day
Trial: 28589238
Drug: Rifaximin (550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (550 mg three times daily for 2 weeks, followed by two 2-week repeat courses)
Trial: 23142439
Drug: 5mg zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg zoledronic acid intravenous infusion
Trial: 18645274
Drug: Modified-release doxazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release doxazosin 4 mg, once a day in the morning, for 2 years
Trial: 18645274
Drug: Bladder catheterization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder catheterization without medication
Trial: 12548324
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single course of corticosteroids (two 12 mg doses of betamethasone given IM 24 hours apart, or four 6 mg doses of dexamethasone given IM 12 hours apart)
Trial: 11049894
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) administered in two bolus doses of 10 mg/kg each, plus a continuous infusion of 1.0 mg/kg/h for 10 hours after the first bolus.
Trial: 11049894
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) administered as described above.
Trial: 28277138
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg carnitine supplements
Trial: 20222892
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine (TRESIVAC(R)) containing Leningrad-Zagreb mumps strain
Trial: 12152000
Drug: Enfuvirtide 45
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide 45 mg (subcutaneous)
Trial: 12152000
Drug: Enfuvirtide 90
RxNorm normalized name: enfuvirtide 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide 90 mg (subcutaneous)
Trial: 12152000
Drug: Enfuvirtide 180
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide 180 mg (subcutaneous)
Trial: 12152000
Drug: Enfuvirtide 90
RxNorm normalized name: enfuvirtide 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide 90 mg (intravenous)
Trial: 10202343
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP; 800 microg/day)
Trial: 10202343
Drug: Inhaled beta2‐agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta2‐agonists alone
Trial: 11086
Drug: Cimetidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (4 X 200 mg/d p.o.)
Trial: 23473350
Drug: Lurasidone 40
RxNorm normalized name: lurasidone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40 mg/d for 2 weeks
Trial: 23473350
Drug: Lurasidone 80
RxNorm normalized name: lurasidone 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 80 mg/d for 2 weeks
Trial: 23473350
Drug: Lurasidone 40
RxNorm normalized name: lurasidone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2
Trial: 23473350
Drug: Lurasidone (flexibly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (flexibly dosed 40-120 mg/d for subsequent 4 weeks)
Trial: 17420681
Drug: Intensive cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cognitive-behavioral therapy (CBT) - 14 sessions of daily psychotherapy
Trial: 17420681
Drug: Weekly cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cognitive-behavioral therapy (CBT) - 14 sessions of weekly psychotherapy
Trial: 17420681
Drug: Intensive cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cognitive-behavioral therapy (CBT)
Trial: 17420681
Drug: Weekly cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cognitive-behavioral therapy (CBT)
Trial: 15136305
Drug: Moderate or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate or severe reductions in GFR (30-59 mL/min per 1.73 m² and <29 mL/min per 1.73 m²)
Trial: 15136305
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in GFR of 10 mL/min per 1.73 m²
Trial: 15136305
Drug: GFR of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR of approximately 60 to 70 mL/min per 1.73 m²
Trial: 9551245
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg once daily for 5 days
Trial: 9551245
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg divided into three doses for 5 days
Trial: 9551245
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg once daily
Trial: 9551245
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg divided into three doses
Trial: 7936839
Drug: N-terminal propeptide
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-terminal propeptide of type III procollagen (PIIINP) concentration measured by Fab'-fragment and whole antibody-based RIA assay in cord serum and amniotic fluid
Trial: 3215203
Drug: Theophylline elixir
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline elixir
Trial: 17068392
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg bid
Trial: 27325335
Drug: Bevacizumab (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (lower dose 7.5 mg/kg)
Trial: 24735616
Drug: Outpatient cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient cognitive behavioral therapy group
Trial: 16042894
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily for up to 5 years
Trial: 16042894
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of lamivudine therapy after HBeAg seroconversion
Trial: 7852463
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of empiric therapy
Trial: 26938920
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (bLF) 100 mg per day
Trial: 21443612
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group 1 (T(1), implant diameter 4.3 mm)
Trial: 21443612
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group 2 (T(2), implant diameter 4.8 mm)
Trial: 21443612
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group 3 (T(3), implant diameter 5.5 mm)
Trial: 21443612
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (implant diameter 3.8 mm)
Trial: 20813541
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using phthalocyanine derivatives as photosensitizers in group L (liposomes)
Trial: 20813541
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) in group L (liposomes)
Trial: 20813541
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) in group N (nanoemulsions)
Trial: 17003366
Drug: Intensive intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intrathecal chemotherapy (standard-risk patients)
Trial: 8636369
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg, twice daily)
Trial: 24474180
Drug: Chloroprocaine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 1.0 mL (Group A)
Trial: 24474180
Drug: Chloroprocaine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 0.8 mL (Group B)
Trial: 24474180
Drug: Chloroprocaine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 0.6 mL (Group C)
Trial: 20308670
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with chemotherapy (EC-T[X])
Trial: 20308670
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (HER2-negative tumors treated with the same chemotherapy without trastuzumab)
Trial: 12100089
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rizatriptan
Trial: 7485936
Drug: PCA +
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA + C (continuous infusion of morphine 1 mg/hr)
Trial: 7485936
Drug: PCA (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA (normal saline infusion)
Trial: 30252061
Drug: DMAU 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAU 400 mg
Trial: 30252061
Drug: Control 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control 400 mg
Trial: 30252061
Drug: DMAU (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAU (various doses: 0, 100, 200, 400 mg)
Trial: 28511660
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg once daily for up to 28 days)
Trial: 28511660
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets for up to 28 days)
Trial: 26091830
Drug: Ropivacaine 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.50% (30 cc) + placebo
Trial: 26091830
Drug: Ropivacaine 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 μg/kg
Trial: 12837869
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV)
Trial: 22496101
Drug: Oral Losec
RxNorm normalized name: Losec
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Losec MUPS for a period of 2 months
Trial: 22496101
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin C tablet for a period of 2 months
Trial: 17335366
Drug: Subgingival chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival chlorhexidine (CHX) varnish administration
Trial: 17335366
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral hygiene instructions and same-day full-mouth root planing)
Trial: 15204012
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg xaliproden
Trial: 15204012
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg xaliproden with riluzole
Trial: 12226965
Drug: Behavioral strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral strategy to enhance adherence to daily monitoring
Trial: 9843529
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (beta-estradiol 2 mg/tablet, 3 tablets/day for 3 days)
Trial: 8305322
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment applied twice daily
Trial: 3059274
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg/day and Penicillin 3 M UI/day
Trial: 3059274
Drug: Cephalothin 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin 250 mg, Gentamicin 20 mg, and Bacitracin 150 UI
Trial: 24491880
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks
Trial: 21396703
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec three times a week (starting dose 20 U per injection)
Trial: 21396703
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec once a day (starting dose 10 U; group A)
Trial: 21396703
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec once a day (starting dose 10 U; group B)
Trial: 21396703
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once a day (starting dose 10 U)
Trial: 19905945
Drug: Experimental combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental combined regenerative therapy (ET)
Trial: 14628982
Drug: Controlled-release paroxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release paroxetine (paroxetine CR) up to 50 mg/day
Trial: 14628982
Drug: Immediate-release paroxetine
RxNorm normalized name: paroxetine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release paroxetine (paroxetine IR) up to 40 mg/day
Trial: 10995147
Drug: Combined rectus
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined rectus sheath and ilioinguinal blocks with bupivacaine 0.25% with adrenaline 1:400,000, up to 60 ml depending on patient's weight.
Trial: 7783888
Drug: Sodium dichloroacetate
RxNorm normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium dichloroacetate (DCA) treatment
Trial: 2213636
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg/day) administered at 7 a.m.
Trial: 2213636
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg/day) administered at 11 p.m.
Trial: 2213636
Drug: Control (light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (light therapy not specified in the abstract)
Trial: 352200
Drug: Racemic epinephrine
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic epinephrine 4.5 mg
Trial: 352200
Drug: Racemic epinephrine
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic epinephrine 9 mg
Trial: 31014369
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Trial: 31014369
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Trial: 28516342
Drug: Oxycodone 10-mg
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 10-mg product under fasting conditions
Trial: 28516342
Drug: Oxycodone 10-mg
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 10-mg product under fed conditions
Trial: 25375652
Drug: Desvenlafaxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50 mg/d and 100 mg/d)
Trial: 22524834
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus chemotherapy (TP) group (Taxotere 35 mg/m2 once weekly, Cisplatin 20 mg/m2 once weekly)
Trial: 24855368
Drug: ERN/LRPT 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT 1 g/20 mg
Trial: 19602880
Drug: N-ER 1
RxNorm normalized name: (Alginate)n+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-ER 1 g (Niaspan(R))
Trial: 17331753
Drug: 2.5% lidocaine/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine/2.5% prilocaine (EMLA) cream